Treatment schedules for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration

To investigate the effects of non-monthly versus monthly intravitreal injection of an anti-VEGF agent on best-corrected visual acuity (BCVA) in people with newly diagnosed nAMD at one-year follow-up.

This is a protocol.

Share/Save